These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 9816636)

  • 21. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
    Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
    Hu XC; Day W; Jones B; Loo WT; Chow LW
    Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Squamous cell carcinoma antigen, tumor associated trypsin inhibitor and tissue polypeptide specific antigen in follow up of stage III cervical cancer.
    Gitsch G; Kainz C; Joura E; Fröhlich B; Bieglmayr C; Tatra G
    Anticancer Res; 1992; 12(4):1247-9. PubMed ID: 1503417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
    Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
    Pan QR; Zhang X; Xu ZF; Zheng S
    Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients.
    Schuurman JJ; Bong SB; Einarsson R
    Anticancer Res; 1996; 16(4B):2169-72. PubMed ID: 8694538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
    Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
    J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
    Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
    J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
    Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
    Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma.
    Nagler RM; Barak M; Peled M; Ben-Aryeh H; Filatov M; Laufer D
    Cancer; 1999 Mar; 85(5):1018-25. PubMed ID: 10091783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum evaluation of interleukin 6 in ovarian cancer patients.
    Tempfer C; Zeisler H; Sliutz G; Haeusler G; Hanzal E; Kainz C
    Gynecol Oncol; 1997 Jul; 66(1):27-30. PubMed ID: 9234916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
    Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
    Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
    Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum M3/M21 in ovarian cancer patients.
    Tempfer C; Hefler L; Haeusler G; Sliutz G; Hanzal E; Reinthaller A; Kainz CH
    Br J Cancer; 1997; 76(10):1387-9. PubMed ID: 9374388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical usefulness of serum and immunohistochemical markers in patients with stage Ia and Ic ovarian cancer.
    Muramatsu T; Mukai M; Sato S; Tajima T; Nagase E; Ikeda M; Goya K; Shida M; Hirasawa T; Murakami M; Shinozuka T
    Oncol Rep; 2005 Oct; 14(4):861-5. PubMed ID: 16142343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical study of serum tissue polypeptide-specific antigen in breast cancer].
    Zheng H; He BF; Luo RC; You CX; Mai GF; Lu HF
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug; 23(8):823-5. PubMed ID: 12919909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker.
    Chang WC; Hung YC; Kao CH; Yen RF; Shen YY; Lin CC
    Neoplasma; 2002; 49(5):329-33. PubMed ID: 12458332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.